Cambridge Healthtech Institute’s 2nd Annual
Gene Therapy Bioproduction
Developing Scalable, Cost-Effective Gene Therapy Manufacturing Processes
Part of CHI's Ninth Annual The Bioprocessing Summit

August 24-25, 2017 | Westin Copley Place | Boston, MA


It is an exciting time for gene therapy: therapies on the market, encouraging clinical data and a long list of pharma collaborations. Pricing and reimbursement takes a majority of the headlines but equally important is producing these therapies in a scalable, cost-effective and robust way, all the while developing a clear CMC and characterization profile that satisfies the regulators.

Cambridge Healthtech Institute’s Gene Therapy Bioproduction meeting takes a practical, case-study driven approach to the process development, scale-up and production of gene therapies, tackling key topics such as AAV, lentivirus and retrovirus process development and scale-up, CMO management from early to late-stage development.

Preliminary Agenda


Process Development Strategies for Lentivirus-Based Processes


KEYNOTE PRESENTATION:
Process Validation and Lifecycle Management

Michele Myers, Ph.D., Senior Director, Cell and Gene Therapy Platform CMC, GlaxoSmithKline


Lentivirus Development and Scale-Up

Jesse Milling, Ph.D., Scientist II, bluebirdbio

Strategies to Deliver Scalable and Reliable Lentiviral Vector Biomanufacturing

Jeffrey Bartlett, Ph.D., CSO, Calimmune Inc.


Process Development Strategies for Other Viruses

Retroviral Vector Process Development for CAR-T Applications

Paulo Fernandes, Ph.D., Senior Scientist, Process Development, Autolus


Process Development Strategies for AAV-Based Processes

Considerations and Challenges When Establishing a New Manufacturing Facility

Lance Weed, Ph.D., Vice President, US Operations, UniQure

Manufacturing Considerations for AAV Gene Therapies

K. Reed Clark, Ph.D., Senior Vice President, Pharmaceutical Development, Dimension Therapeutics


Development and Production Challenges in Gene Editing

Gene Editing: Development and Production Challenges

Ken LeClair, Ph.D., Vice President, Technical Development and Manufacturing, Editas Medicine

Advantages and Challenges of Early Phase Clinical Manufacturing in an Academic Setting

Johannes C.M. van der Loo, Ph.D., Director, Clinical Vector Core, The Raymond G. Perelman Center for Molecular and Cellular Therapies, Children’s Hospital of Philadelphia

Separation of Virus, VLP and Extracellular Particles

Alois Jungbauer, Ph.D., Professor, Institute of Biotechnology, University of Natural Resources and Life Sciences (BOKU)

Formulation Development for AAV Gene Therapy Application

Tanvir Tabish, Head, Drug Product Development for Gene Therapy, Device and Combination Products, Shire

BIA separationsHigh Resolution Monolithic Columns - Enabling Tool for Understanding Viral Structures and Their Purity

Ales Strancar, CEO, BIA Separations


Scaling-Up and Industrializing Gene Therapies

Presentations to be Announced




For more details on the conference, please contact:
Daniel Barry
Senior Conference Director
Phone: 781-247-6266
Email: dbarry@healthtech.com

For media partnership opportunities, please contact:
Kaushik Chaudhuri
Director of Product Marketing
Phone: 781-972-5419
Email: kchaudhuri@healthtech.com

For exhibit & sponsorship opportunities, please contact:

Companies A-K
Sherry Johnson
Business Development Manager
Phone: 781-972-1359
Email: sjohnson@cambridgeinnovationinstitute.com

Companies L-Z
Carolyn Benton
Business Development Manager
Phone: 781-972-5412
Email: cbenton@healthtech.com

OutlookYouTubeFacebookLinkedInTwitter #BPSMT

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  


Event at a Glance
Event at a Glance


Celebrating 25 Years


 

Premier Sponsor

Unchained Labs(1)